Exact Mass: 481.177
Exact Mass Matches: 481.177
Found 166 metabolites which its exact mass value is equals to given mass value 481.177
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Pranlukast
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent
Rosuvastatin
Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Pranlukast
Pranlukast is only found in individuals that have used or taken this drug. It is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
(3R,5R)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
(3S)-3-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]-6-fluoro-4,5-dioxohexanoic acid
Benzyloxycarbonylvalyl-alanyl-aspartyl Fluoromethyl Ketone
Rosuvastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 2802
Ala Asp Asn Tyr
Ala Asp Tyr Asn
Ala Asn Asp Tyr
Ala Asn Tyr Asp
Ala Tyr Asp Asn
Ala Tyr Asn Asp
Cys Cys Arg Thr
Cys Cys Thr Arg
Cys Arg Cys Thr
Cys Arg Thr Cys
Cys Thr Cys Arg
Cys Thr Arg Cys
Asp Ala Asn Tyr
Asp Ala Tyr Asn
Asp Phe Asn Ser
Asp Phe Ser Asn
Asp Gly Gln Tyr
Asp Gly Tyr Gln
Asp Asn Ala Tyr
Asp Asn Phe Ser
Asp Asn Ser Phe
Asp Asn Tyr Ala
Asp Gln Gly Tyr
Asp Gln Tyr Gly
Asp Ser Phe Asn
Asp Ser Asn Phe
Asp Tyr Ala Asn
Asp Tyr Gly Gln
Asp Tyr Asn Ala
Asp Tyr Gln Gly
Glu Gly Asn Tyr
Glu Gly Tyr Asn
Glu Asn Gly Tyr
Glu Asn Tyr Gly
Glu Tyr Gly Asn
Glu Tyr Asn Gly
Phe Asp Asn Ser
Phe Asp Ser Asn
Phe Asn Asp Ser
Phe Asn Ser Asp
Phe Ser Asp Asn
Phe Ser Asn Asp
Gly Asp Gln Tyr
Gly Asp Tyr Gln
Gly Glu Asn Tyr
Gly Glu Tyr Asn
Gly Asn Glu Tyr
Gly Asn Tyr Glu
Gly Gln Asp Tyr
Gly Gln Tyr Asp
Gly Tyr Asp Gln
Gly Tyr Glu Asn
Gly Tyr Asn Glu
Gly Tyr Gln Asp
Asn Ala Asp Tyr
Asn Ala Tyr Asp
Asn Asp Ala Tyr
Asn Asp Phe Ser
Asn Asp Ser Phe
Asn Asp Tyr Ala
Asn Glu Gly Tyr
Asn Glu Tyr Gly
Asn Phe Asp Ser
Asn Phe Ser Asp
Asn Gly Glu Tyr
Asn Gly Tyr Glu
Asn Ser Asp Phe
Asn Ser Phe Asp
Asn Tyr Ala Asp
Asn Tyr Asp Ala
Asn Tyr Glu Gly
Asn Tyr Gly Glu
Gln Asp Gly Tyr
Gln Asp Tyr Gly
Gln Gly Asp Tyr
Gln Gly Tyr Asp
Gln Tyr Asp Gly
Gln Tyr Gly Asp
Arg Cys Cys Thr
Arg Cys Thr Cys
Arg Thr Cys Cys
Ser Asp Phe Asn
Ser Asp Asn Phe
Ser Phe Asp Asn
Ser Phe Asn Asp
Ser Asn Asp Phe
Ser Asn Phe Asp
Thr Cys Cys Arg
Thr Cys Arg Cys
Thr Arg Cys Cys
Tyr Ala Asp Asn
Tyr Ala Asn Asp
Tyr Asp Ala Asn
Tyr Asp Gly Gln
Tyr Asp Asn Ala
Tyr Asp Gln Gly
Tyr Glu Gly Asn
Tyr Glu Asn Gly
Tyr Gly Asp Gln
Tyr Gly Glu Asn
Tyr Gly Asn Glu
Tyr Gly Gln Asp
Tyr Asn Ala Asp
Tyr Asn Asp Ala
Tyr Asn Glu Gly
Tyr Asn Gly Glu
Tyr Gln Asp Gly
Tyr Gln Gly Asp
3-Ethyl-5-methyl-4-(2-chlorophenyl)-2-(2,2-diethoxy-ethoxymethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Bifeprunox Mesylate
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Bifeprunox mesylate is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pKis of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC50 of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox mesylate is an antipsychotic for the research of schizophrenia[1][2].
(E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
(3r,5r,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
Cbz-DL-Val-DL-Ala-DL-Asp-AcF
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D009676 - Noxae > D000477 - Alkylating Agents > D000590 - Amino Acid Chloromethyl Ketones D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D020011 - Protective Agents
(3S)-3-[[(2S)-2-[[(2S)-2-Amino-3-methylbutanoyl]amino]propanoyl]-phenylmethoxycarbonylamino]-6-fluoro-4,5-dioxohexanoic acid
Arg-Thr-Cys-Cys
A tetrapeptide composed of L-arginine, L-threonine and two L-cysteine units joined in sequence by peptide linkages.